AltMountain

AVGSF - Glympse Bio 2020

Boston, MA · CIK 1810710
506(c)
Status: no Form D since Jun 2020. Funds file a Form D when they begin selling and amend it each year while the offering continues, so this fund has most likely stopped raising money. It may still be investing, or it may have closed or been dissolved. The details below are from its latest filing, kept here as a record.

AVGSF - Glympse Bio 2020 is a venture capital fund based in Boston, Massachusetts. According to its most recent Form D, filed Jun 1, 2020, it has sold $2,724,999 of interests to 106 investors since its first sale in May 2020. The minimum investment it accepts from an outside investor is $10,000. It relies on the Section 3(c)(1) exclusion, which limits it to 100 beneficial owners, typically accredited investors. The offering uses Rule 506(c), which permits general advertising to investors verified as accredited. Related persons named in the filing include Michael Collins.

Total raised
$2,724,999Cumulative sales reported on Form D
Investors
106
First sale
May 29, 2020
Minimum investment
$10,000
Who can invest
Accredited investorsSection 3(c)(1): up to 100 beneficial owners
Offering exemption
Rule 506(c)May advertise; investors must be verified as accredited
Key people and entities
Michael Collins
Latest Form D
Jun 1, 2020

From SEC filings, not verified. This page republishes the fund's Form D as filed. It is not an offer, solicitation or recommendation, and AltMountain has not reviewed the fund. “Raised” is cumulative sales, not current assets or performance. Returns are not part of SEC filings. Private funds are speculative, illiquid and generally limited to accredited investors or qualified purchasers. Full disclosures · Request a correction⁠​​‌‌‌‌‌‌‌‌​​​​​​​​​‌⁠

Questions about AVGSF - Glympse Bio 2020

What is the minimum investment for AVGSF - Glympse Bio 2020?

According to its latest Form D, filed Jun 1, 2020, the minimum investment AVGSF - Glympse Bio 2020 accepts from an outside investor is $10,000.

Who can invest in AVGSF - Glympse Bio 2020?

AVGSF - Glympse Bio 2020 is generally open only to accredited investors, and it may have no more than 100 beneficial owners because it relies on Section 3(c)(1). It uses Rule 506(c), so it may advertise, but every investor must be verified as accredited.

How much has AVGSF - Glympse Bio 2020 raised?

AVGSF - Glympse Bio 2020 reports $2,724,999 sold from 106 investors on its Form D filed Jun 1, 2020. This is cumulative sales since the offering began, not current assets or performance.

Where is AVGSF - Glympse Bio 2020 based?

AVGSF - Glympse Bio 2020 is based in Boston, Massachusetts.

When did AVGSF - Glympse Bio 2020 launch?

AVGSF - Glympse Bio 2020 reports its first sale in May 2020.

Size compared with every venture capital fund

Raised more than 74% of the 533 venture capital funds based in Massachusetts, and more than 75% of all 14,877 that report sales.

More venture capital funds in Boston

Similar-size venture capital funds in Massachusetts

All venture capital funds in Massachusetts